NICE (The National Institute for Health and Care Excellence) draft guidance recommends Olysio (simeprevir) from Janssen Cilag, in combination with...
Janssen Research & Development has submitted a Supplemental New Drug Application to the FDA for Olysio (simeprevir) in combination with...
Janssen R&D Ireland (Janssen) today announced the presentation of additional data for the NS3/4A protease inhibitor OLYSIO® (simeprevir) at the...
The FDA has approved Olysio (simeprevir), from Janssen R&D, for the treatment of chronic Hepatitis C infection as part of...
The FDA has approved Olysio (simeprevir) in combination with Sovaldi (sofosbuvir), from Medivir and Janssen, as an all-oral, interferon- and...
New Phase III data for the once-daily Olysio (simeprevir), from Medivir, for the treatment of patients with Hepatitis C, show...
Janssen Sciences has announced results for its Hepatitis C treatment Olysio plus Sovaldi (simeprevir plus sofosbuvir) in Genotype 1 HCV...
Janssen-Cilag has announced that Olysio (simeprevir) has been granted marketing authorisation by the European Commission (EC) for the treatment of...
Janssen has submitted a supplemental New Drug Application to the FDA to update the label for once-daily, all-oral Olysio (simeprevir),...
In an early benefit assessment, the German Institute for Quality and Efficiency in Health Care (IQWiG) has found indications and...